The tLyp1‐modified nanoparticles were rapidly internalized into Tregs instead of tumor cells or CD8+ T cells, which led to stronger antitumor effect toward B16 tumors in comparison with nanoparticles without Treg‐targeting peptide. This evidence concerns the gene CD8A and neoplasm.